References
- Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis.203(1), 75–84 (2011).
- Papa A, Danis K, Baka A et al. Ongoing outbreak of West Nile virus infections in humans in Greece, July – August 2010. Euro Surveill.15(34), pii: 19644 (2010).
- Sirbu A, Ceianu CS, Panculescu-Gatej RI et al. Outbreak of West Nile virus infection in humans, Romania, July to October 2010. Euro Surveill.16(2), pii: 19762 (2011).
- Beasley DW. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy3(2), 269–285 (2011).
- Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine28(3), 632–649 (2010).
- Arroyo J, Miller C, Catalan J et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol.78(22), 12497–12507 (2004).
- Monath TP, Liu J, Kanesa-Thasan N et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA103(17), 6694–6699 (2006).
- Smith HL, Monath TP, Pazoles P et al. Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J. Infect. Dis.203(4), 513–522 (2011).
- Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease – United States, 1999–2008. MMWR Surveill. Summ.59(2), 1–17 (2010).
- Monath TP, Cetron MS, McCarthy K et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum. Vaccin.1(5), 207–214 (2005).
- Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine23(25), 3232–3235 (2005).
- Li L, Barrett AD, Beasley DW. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology335(1), 99–105 (2005).
- Petersen LR, Roehrig JT. Flavivirus DNA vaccines – good science, uncertain future. J. Infect. Dis.196(12), 1721–1723 (2007).
- Martina BE, Koraka P, Osterhaus AD. West Nile Virus: is a vaccine needed? Curr. Opin. Investig. Drugs11(2), 139–146 (2010).